A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
for Locally Advanced Head and Neck Squamous Cell Carcinoma
70 locations incl. Birmingham
Sponsor: AstraZeneca
Sex: All·Age: 18 - 130
Code: NCT06129864·Phase 3·Recruiting